Rhythm Pharmaceuticals

RYTM Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$86.29

-2.08% today

52W: $45.91 – $122.20

52W Low: $45.91 Position: 52.9% 52W High: $122.20

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

31.05x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$5.9B

Market Capitalization

Revenue Growth

36.9%

YoY Revenue Growth

Profit Margin

-103.57%

Net profit margin

ROE

-90.45%

Return on Equity

Beta

2.14

Market sensitivity

Short Interest

12.18%

% of float sold short

Avg. Volume

833,913

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

15 analysts

Avg. Price Target

$137.27

+59.08% upside

Target Range

$105.00 – $158.00

About the Company

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficie

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 414 Exchange: NGM